Loading
NASDAQHealthcareBiotechnology
Latest quote
$28.3422
+$1.1422 · +4.20%
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Regular session
$28.45
+$1.25 · +4.60%
Regular session · ET · Market data may be delayed.
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Day range
Current $28.45
52-week range
Current $28.45
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
25
Expensive
Sentiment
73
Bullish
Risk
36
Moderate Risk
Momentum
65
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Day range
Current $28.45
52-week range
Current $28.45
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | 87.37M USD | 380.79M USD | 22.23M USD | — |
| Cost of goods sold | 525K USD | 42.16M USD | 25.44M USD | 2.99M USD | — |
| Gross profit | −525K USD | 45.22M USD | 355.35M USD | 19.24M USD | — |
| Research and development | 90.4M USD | 104.08M USD | 128.19M USD | 93.45M USD | 44.04M USD |
| Selling, general, and administrative | 62.89M USD | 114.33M USD | 188.36M USD | 127.13M USD | 38.93M USD |
| Operating expenses | 152.77M USD | 359.95M USD | 316.54M USD | 220.58M USD | 82.69M USD |
| Interest income | 9.3M USD | 13.81M USD | 16.16M USD | 4.29M USD | 36K USD |
| Depreciation and amortization | 525K USD | 904K USD | 1.09M USD | 487K USD | 52K USD |
| Operating income | −153.29M USD | −314.73M USD | 38.8M USD | −201.34M USD | −82.69M USD |
| Net income | −144.74M USD | −301.74M USD | 49.27M USD | −198.38M USD | −87.93M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$52.20
83.48% upside| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Mar 28, 2018 | $0.42Quarterly | — | Apr 2, 2018 |
Dividend | Dec 28, 2017 | $0.36Quarterly | — | Jan 2, 2018 |
Dividend | Sep 28, 2017 | $0.24Quarterly | — | Oct 2, 2017 |
Ex-dividend Mar 28, 2018
$0.42
Quarterly
Payment Apr 2, 2018
Ex-dividend Dec 28, 2017
$0.36
Quarterly
Payment Jan 2, 2018
Ex-dividend Sep 28, 2017
$0.24
Quarterly
Payment Oct 2, 2017
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI127.91M0.01%2.3T USD0.03%$381.97+0.63%
iShares Russell 2000 ETFIWM74.51M0.10%77.7B USD0.19%$279.35+0.64%
Vanguard Extended Market ETFVXF38.81M0.04%95.4B USD0.05%$235.04+0.82%
iShares Russell 2000 Growth ETFIWO26M0.19%14.04B USD0.24%$357.36+1.10%
iShares Biotechnology ETFIBB22.39M0.21%10.41B USD0.44%$206.6+3.05%
Vanguard Russell 2000 ETFVTWO20.1M0.11%18B USD0.06%$112.83+0.65%
Schwab U.S. Small-Cap ETFSCHA14.9M0.07%21.73B USD0.03%$32.845+0.57%
iShares U.S. Pharmaceuticals ETFIHE9.74M0.64%1.53B USD0.37%$100.29+1.45%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAiShares U.S. Pharmaceuticals ETFIHEAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
